Breaking Finance News

BidaskClub upgraded Blueprint Medicines Corp (NASDAQ:BPMC) to Buy in a report released today.

BidaskClub has upgraded Blueprint Medicines Corp (NASDAQ:BPMC) to Buy in a report released on 6/20/2017.

Just yesterday Blueprint Medicines Corp (NASDAQ:BPMC) traded 2.23% higher at $42.39. Blueprint Medicines Corp’s 50-day moving average is $50.16 and its 200-day moving average is $45.28. The last stock price is down 27.69% from the 200-day moving average, compared to the Standard & Poor's 500 Index which has increased 0.04% over the same time period. 825,820 shares of BPMC traded hands, up from an average trading volume of 477,880

Recent Performance Chart

Blueprint Medicines Corp (NASDAQ:BPMC)

Blueprint Medicines Corp has 52 week low of $25.08 and a 52 week high of $58.67 and has a market capitalization of $0.

In addition to BidaskClub reporting its stock price target, a total of 3 brokerages have issued a research note on the company. The average stock price target is $31.00 with 1 brokerage rating the stock a strong buy, 2 brokerages rating the stock a buy, 1 brokerage rating the stock a hold, 0 brokerages rating the stock a underperform, and finally 0 brokerages rating the stock a sell.

Brief Synopsis On Blueprint Medicines Corp (NASDAQ:BPMC)

Blueprint Medicines Corporation is a biopharmaceutical company. The Company focuses on patients with genomically defined diseases driven by abnormal kinase activation. It focuses on crafting drug candidates that provide clinical responses to patients without adequate treatment options. It has developed a small molecule drug pipeline in cancer and a genetic disease. Its drug candidate, BLU-285, targets KIT, including Exon 17 mutations, and targets PDGFRa, including the D842V mutation. These mutations activate receptor tyrosine kinases that are drivers of cancer and proliferative disorders, including gastrointestinal stromal tumors (GIST), and systemic mastocytosis (SM). Its drug candidate BLU-554 targets FGFR4, a kinase that is activated in a defined subset of patients with hepatocellular carcinoma (HCC), the common type of liver cancer. It is engaged in developing BLU-667, a drug candidate that targets RET, a receptor tyrosine kinase that is activated by mutations or translocations.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with MarketBeat.com's FREE daily email newsletter.

Leave a Reply

Your email address will not be published. Required fields are marked *